Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue Prior Auth Drug Routing & Policy Upda…
    Ask Trek AI about this page
    CurrentFlorida BluePolicy N/A

    Prior Authorization Program Information and Authorization Forms

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists numerous drug products with routing (CoverMyMeds vs Availity) and preferred-agent notes (biosimilars, insulin products that do not require PA).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerFlorida Blue
    PolicyPrior Authorization Program Information and Authorization Forms
    Policy CodePolicy N/A
    Change TypeAdministrative/drug-list update (informational)
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization requests via the channel indicated for each drug (CoverMyMeds or Availity) or follow routing notes such as 'For Non-Fertility related diagnoses - SEND to Availity'.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes noted; this section is an administrative listing of drugs with routing and preference notes.

    150+Drugs listed in this part
    11Insulin products listed as preferred (no PA)
    3Preferred growth-hormone agents
    2ESA preferred examples
    2Primary submission channels

    Policy fragment summary

    This administrative fragment lists numerous drugs and maps each to the electronic prior-authorization submission platform to be used (primarily CoverMyMeds or Availity), and highlights preferred biosimilars and insulin products that do not require prior authorization. It conveys examples of preferred substitutions (e.g., Procrit/Retacrit preferred over Aranesp/Epogen; Nivestym/Zarxio preferred over Neupogen/Granix; Norditropin, Genotropin, Omnitrope preferred within growth-hormone class), and names insulin agents that are preferred and do not require prior authorization (examples include Fiasp, Humalog, Humalog Mix, Humulin 70/30, Humulin N, Humulin R, Lyumjev, Novolin 70/30, Novolin N, Novolin R, Novolog, Novolog 70/30). The operational purpose is administrative routing (directing providers which portal to use for PA requests) and to provide formulary preferred-agent guidance. Current policy status is CURRENT and providers are instructed to use the designated channel per drug (CoverMyMeds or Availity) per the listing.

    Summary
    Drugs listed in this part150+
    Primary submission channels2
    Insulin products listed as preferred (no PA required)11
    Class preferred-agent examplesNorditropin / Genotropin / Omnitrope; Procrit / Retacrit; Nivestym / Zarxio
    Operational instructionRoute prior authorizations to the portal indicated per drug (CoverMyMeds or Availity).

    Drug lists, preferred agents, and portal routing

    Preferred agents / routing notes (drug-level)NDC
    KALYDECO
    KANJINTI
    KEVZARA
    KEYTRUDA QLEX
    KHAPZORY
    KHINDIVI
    KINERET
    KISQALI
    KLISYRI
    KOATE
    1–10 of 255
    1/26

    What providers must do

    Prior Authorization

    Use specified submission channel

    Submit prior authorization requests via the channel indicated for each drug (CoverMyMeds or Availity) or follow routing notes such as 'For Non-Fertility related diagnoses - SEND to Availity'.

    • Follow per-drug portal indicated (CoverMyMeds or Availity)
    Documentation Required

    Send prior authorization via Availity for non-fertility diagnoses

    For many listed drugs (notably non-fertility related diagnoses and several named products) the instruction is to send prior authorization requests to Availity; providers should route PA accordingly.

    • Examples: MENOPUR (For Non-Fertility related diagnoses - SEND to Availity), PREGNYL W/DILUENT BENZYL ALCOHOL/NACL (For Non-Fertility related diagnoses - SEND to Availity), NOURIANZ (For Non-Fertility related diagnoses - SEND to Availity)

    Definitions

    Definitions / Key Terms
    CoverMyMedsAn electronic prior authorization submission platform referenced throughout the drug listing.
    AvailityAn electronic portal referenced as the routing destination for many provider-administered or buy-and-bill prior authorization requests.
    CoverMyMeds / Availity (consolidated)When both platforms are mentioned, follow the drug-specific routing note; some products explicitly require sending PAs to Availity for provider-administered drugs or for non‑fertility diagnoses.
    Preferred-agent guidanceEntries note preferred alternatives (e.g., Procrit/Retacrit over Aranesp/Epogen; Nivestym/Zarxio over Neupogen/Granix; Norditropin/Genotropin/Omnitrope in growth‑hormone class).

    This fragment is strictly an administrative routing and reference list that indicates the submission channel for prior authorization requests and notes preferred agents; it does not provide clinical coverage criteria or decision trees. There are no criteria_trees included in this segment; clinical necessity and coverage determinations are handled by the program’s medical-necessity criteria referenced elsewhere.

    Document changes

    Policy Summary
    PayerFlorida Blue
    PolicyPrior Authorization Program Information and Authorization Forms
    Policy CodePolicy N/A
    Change TypeAdministrative/drug-list update (informational)
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization requests via the channel indicated for each drug (CoverMyMeds or Availity) or follow routing notes such as 'For Non-Fertility related diagnoses - SEND to Availity'.
    SourceLink
    On This Page
    Policy fragment summaryDrug lists, preferred agents, and portal routingWhat providers must doDefinitionsDocument changes
    Documentation Required

    Use CoverMyMeds when indicated

    Many drugs reference CoverMyMeds as the platform for prior authorization submissions; providers should use CoverMyMeds where specified.

    • Many listed drugs reference CoverMyMeds for ePA
    • Examples: GAVRETO, GAZYVA, GEFITINIB (from code_groups[2]); OMNITROPE, HYRNUO (from code_groups[5])
    Documentation Required

    Follow preferred-agent guidance where indicated

    When entries indicate preferred alternatives (e.g., Procrit/Retacrit preferred over Aranesp/Epogen; Nivestym/Zarxio preferred over Neupogen/Granix; Norditropin/Genotropin/Omnitrope preferred in class), providers should consider preferred agents per formulary guidance.

    • Procrit and Retacrit preferred over Aranesp and Epogen (example notes present)
    • Nivestym and Zarxio preferred over Neupogen and Granix (noted repeatedly)
    • Norditropin, Genotropin and Omnitrope preferred in the growth-hormone class
    Prior Authorization

    Use designated portals for PA submissions

    Submit prior authorization requests via the indicated portal per drug (CoverMyMeds or Availity) as listed; some products have explicit preferred alternatives noted.

    • Submission must follow the portal listed for each drug (CoverMyMeds or Availity)
    • Some entries specify starter packs or special kits (e.g., PALFORZIA starter kits, PLEGRIDY starter pack, HEPZATO Kit)
    Documentation Required

    Follow preference guidance where indicated

    When preference notes are present (e.g., Humira Abbvie NDCs beginning with 00074, Hadlima; Nivestym and Zarxio preferred over Neupogen and Granix; Procrit and Retacrit preferred over Aranesp and Epogen; Norditropin/Genotropin/Omnitrope preferred for ZOMACTON class), document chosen product rationale.

    • Document rationale when selecting a non-preferred product
    • Example: Humira (Abbvie NDCs beginning with 00074) and Hadlima are noted as preferred in multiple entries